Phase 1/2/3

A new once-daily pill for hypoparathyroidism begins human testing, promising to replace burdensome injections and transform patient care. Is this the future?

A new FDA-cleared device uses water vapor to ablate prostate tissue, showing high efficacy in trials while minimizing life-altering side effects.

With a cash runway into 2027, the biotech firm prepares for critical data on its innovative bispecific antibody pipeline for hard-to-treat solid tumors.

A new biotech spins out with a novel drug class aiming to provide healthier, more durable weight loss and combat cancer-related wasting syndrome.

With a $35 million boost from RA Capital, Equillium extends its cash runway to 2029, fueling the clinical development of its promising oral UC therapy, EQ504.

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

Neurizon Therapeutics has started dosing its promising ALS drug, NUZ-001, in the groundbreaking HEALEY Platform Trial, a pivotal step for patients.

A new collaboration is betting on tiny natural particles to deliver a gene-editing cure for a devastating neurological disorder, bypassing a key medical hurdle.

With stellar clinical data and a full war chest, Terns is hitting the road to convince investors its leukemia drug, TERN-701, is a true disruptor.

Promising trial data for onvansertib offers new hope for colorectal cancer patients, yet leadership changes and financial hurdles cloud the path forward.

A planned reverse merger for promising vaccine developer SVF Vaccines has collapsed after Nasdaq rejected the deal, leaving its lead investor scrambling.

Avacta's pre|CISION therapy shows faster, more potent, and more selective tumor targeting than Enhertu in an AI-driven study, paving the way for 2026 trials.

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.

A Malaysian biotech's new study shows its NK cell therapy is safe, using a novel, low-cost method that could make advanced cancer treatment affordable worldwide.

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.

Clinical-stage biotech BioVie announces its novel anti-inflammatory drug, bezisterim, will be featured at a key psychiatric conference for its potential.

With a strong cash position, Arcus Biosciences heads into a pivotal year as investors await critical data on its promising cancer and autoimmune pipeline.

After a decade-long battle with Stage 4 cancer, one patient's cure spotlights a revolutionary immunotherapy and its potential to change cancer treatment.

With its Phase 1 trial fully enrolled, Senti Bio’s logic-gated CAR-NK therapy shows deep, durable remissions, charting an expedited path for R/R AML.

With its foundational drug a success, Madrigal bets billions on next-gen siRNA tech, aiming to fuse it with Rezdiffra and dominate MASH treatment.